Literature DB >> 8438617

Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model.

C P Mallett1, L VanDeVerg, H H Collins, T L Hale.   

Abstract

Five Shigella vaccine candidates (EcSf2a-1, EcSf2a-2, Sfl124, T32-Istrati and SMD) were tested for safety and efficacy in Balb/cJ mice using an intranasal challenge model. Experiments in this model suggest that (i) the relative attenuation of vaccines can be determined in mice by intranasal inoculation, (ii) all vaccines tested elicited antibacterial mucosal immunity protecting against pulmonary infection with Shigella flexneri 2a, (iii) protection was associated with serum IgA and/or IgG antibody recognizing the 2a somatic antigen.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8438617     DOI： 10.1016/0264-410x(93)90016-q

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  32 in total

1.  Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Authors:  R W Kaminski; M Wu; K R Turbyfill; K Clarkson; B Tai; A L Bourgeois; L L Van De Verg; R I Walker; E V Oaks
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

2.  Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Authors:  S R Klee; B D Tzschaschel; I Fält; A Kärnell; A A Lindberg; K N Timmis; C A Guzmán
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 3.  Progress and pitfalls in Shigella vaccine research.

Authors:  Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein; Alessio Fasano; Karen L Kotloff; Myron M Levine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

Review 4.  The pathogenesis of Shigella flexneri infection: lessons from in vitro and in vivo studies.

Authors:  D J Philpott; J D Edgeworth; P J Sansonetti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

5.  Clearance of Shigella flexneri infection occurs through a nitric oxide-independent mechanism.

Authors:  S S Way; M B Goldberg
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.

Authors:  M L Bernardini; J Arondel; I Martini; A Aidara; P J Sansonetti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

7.  Impact of either elevated or decreased levels of cytochrome bd expression on Shigella flexneri virulence.

Authors:  S S Way; S Sallustio; R S Magliozzo; M B Goldberg
Journal:  J Bacteriol       Date:  1999-02       Impact factor: 3.490

8.  Identification of alkA gene related to virulence of Shigella flexneri 2a by mutational analysis.

Authors:  Zhao-Xing Shi; Heng-Liang Wang; Kun Hu; Er-Ling Feng; Xiao Yao; Guo-Fu Su; Pei-Tang Huang; Liu-Yu Huang
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

9.  Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Authors:  Ryan T Ranallo; Robert W Kaminski; Tonia George; Alexis A Kordis; Qing Chen; Kathleen Szabo; Malabi M Venkatesan
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

10.  Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutants.

Authors:  Antonella Cersini; Maria Celeste Martino; Irene Martini; Giacomo Rossi; Maria Lina Bernardini
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.